Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Mitoxantrone Hydrochloride Liposome in Solid Tumors
NCT02043756Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2011
- Primary completion
- Jun 2013
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
01
Overview
Phase 1, open-label trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in solid tumor (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Maximum Tolerated Dose at 3 weeks and Dose-Limiting Toxicity at 3 weeks. Started Aug 2011; status: completed.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02043756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043756.